Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 14;16(1):30.
doi: 10.1186/s13023-021-01677-9.

Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?

Andreas Selberherr  1 , Simon Freermann  2 , Oskar Koperek  3 , Martin B Niederle  4 , Philipp Riss  2 , Christian Scheuba  2 , Bruno Niederle  2
Affiliations

Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?

Andreas Selberherr et al. Orphanet J Rare Dis. .

Abstract

Background: Neuroendocrine neoplasia of the small intestine (siNEN) are frequently diagnosed with liver metastases. The impact of the presence of liver metastases on overall survival and the necessity of surgery for liver metastasis is discussed controversially. The aim of this study is to evaluate and compare the overall long-term survival of patients with siNENs with and without liver metastasis at initial diagnosis and the possible benefit of surgical treatment as compared to active surveillance of metastases. 123 consecutive patients with siNENs were treated between 1965 and 2016. All clinical and histological records were reevaluated including analysis of the proliferation rates in all specimens. The 1-, 5-, 10- and 20-year overall survival was estimated by Kaplan-Meier analysis for patients with and without liver metastasis and according to the type of treatment (surgical vs. surveillance) of liver metastases if present.

Results: The 1-, 5-, 10- and 20-year overall survival rate was 89.0%, 68.4%, 52.8% and 31.0% in patients without and 89.5%, 69.5%, 33.2% and 3.6% in those with liver metastases. No statistically significant differences were observed comparing the two groups. Within the group of patients with liver metastases, the type of treatment (surgical vs. surveillance) was in favor of patients undergoing surgery. Multivariate analysis showed that the presence of liver metastases upon diagnosis was an individual risk factor associated with worse survival.

Conclusion: The presence of liver metastasis at initial diagnosis does not have a statistically significant influence on survival. Surgery for hepatic metastasis seems to show a benefit for overall survival and may be indicated especially in patients symptomatic due to high tumor burden and serotonin hypersecretion to reduce hormone activity.

Keywords: Livermetastasis; NEN; NET; Neuroendocrine neoplasia; Neuroendocrine tumors; Small intestine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Estimated cumulative survival comparing patients without (0) and with (1) liver metastases
Fig. 2
Fig. 2
Estimated cumulative survival comparing patients without (1) and with surgery for liver metastases (2)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–918. doi: 10.1677/ERC-10-0152. - DOI - PubMed
    1. Selberherr A, Niederle MB, Niederle B. Surgical treatment of small intestinal neuroendocrine tumors G1/G2. Visc Med. 2017;33(5):340–343. doi: 10.1159/000477786. - DOI - PMC - PubMed
    1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18. doi: 10.1016/j.ecl.2010.12.005. - DOI - PubMed
    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed
    1. Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist. 2011;16(5):602–613. doi: 10.1634/theoncologist.2011-0002. - DOI - PMC - PubMed